Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-State Pharmacokinetics and Short-Term Efficacy and Safety in HIV-1 Positive Treatment naive Patients.

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-State Pharmacokinetics and Short-Term Efficacy and Safety in HIV-1 Positive Treatment naive Patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ritonavir (Primary) ; Tipranavir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 30 Jan 2009 Planned number of patients changed from 75 to 85 as reported by ClinicalTrials.gov.
    • 17 Jun 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 11 May 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top